Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunoGen, Inc. - Common Stock (NQ: IMGN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
From ImmunoGen
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen, inc (IMGN) Q3 2021 Earnings Call Transcript
IMGN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Recap: Immunogen Q3 Earnings
Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, October 29, 2021 at 06:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
Earnings Outlook For Immunogen
Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2021-10-29. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Scheduled For October 29, 2021
Companies Reporting Before The Bell • Sify Technologies (NASDAQ:SIFY) is expected to report quarterly earnings at $0.02 per share on revenue of $97.70 million. •... 
Via Benzinga
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
From ImmunoGen Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen, inc (IMGN) Q2 2021 Earnings Call Transcript
IMGN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Immunogen Q2 Earnings
Shares of Immunogen (NASDAQ:IMGN) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were down 7.14% year over year to ($0.15),... 
Via Benzinga
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
Earnings Scheduled For July 30, 2021
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its second quarter. • Embraer (NYSE:ERJ) is... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
Immunogen Insights: Return On Capital Employed
Immunogen (NASDAQ:IMGN) reported Q1 sales of $15.71 million. Earnings fell to a loss of $28.92 million, resulting in a 179.18% decrease from last quarter. Immunogen earned $36.52... 
Via Benzinga
Immunogen Insights: Return On Capital Employed
Immunogen (NASDAQ:IMGN) reported Q1 sales of $15.71 million. Earnings fell to a loss of $28.92 million, resulting in a 179.18% decrease from last quarter. Immunogen earned $36.52... 
Via Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
From ImmunoGen Inc.
Via Business Wire
Immunogen Inc (IMGN) Q1 2021 Earnings Call Transcript
IMGN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Immunogen: Q1 Earnings Insights
Shares of Immunogen (NASDAQ:IMGN) decreased 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% over... 
Via Benzinga
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.